Floatz logo

Blu-701

Respiratory Tract Neoplasms

Blueprint Medicines CorporationPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Respiratory Tract Neoplasms cohort.

Asset / SponsorPhaseRating
Carboplatin
Fundación GECP
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Nanfang Hospital, Southern Medical University
Phase 3BB
Pralsetinib, trans-
Hoffmann-La Roche
Phase 3BB
Pembrolizumab
Hoffmann-La Roche
Phase 3B
Docetaxel
University of Turin, Italy
Phase 3B

View all 25 →

Same molecule, other indications

Blu-701 is also rated in:

lung neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
chemotherapy-induced toxicityDormant
CC
Indicative ·
43 / 100
View asset →
respiratory system disorderDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →